LISAvienna: December newsletter available online

Name: _pk_id Used for : Is used to store an unique ID for each user Duration : 13 Months
Name: &nbsp;_pk_ses, _pk_cvar, _pkhsr Used for :&nbsp;Session cookies that store temporary data Duration :&nbsp;30 minutes
Name: mtm_consent Used for : Stores cookie preferences Duration : 30 years

Today’s edition feature headlines from Novid20, invIOs, Valneva, ViruSure, Xund, MedUni Vienna, Solnatide Projekt, Evercyte, myReha, Ares Genetics, famado, Solgenium, Sofy, contextflow, Scarletred, cogvis, Cebina, BlueSky Immunotherapies, Semperit, HeartBeat.bio, IMBA; Origimm and Lifebrain.

In addition, we update you on the trade shows and partnering conferences we plan to attend in 2022, media articles, events and funding deadlines.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.

LISAvienna: December newsletter available online

Zweiter Workshop des One Health Network Austria an der Vetmeduni

Uni Vienna: Conservation paradox: Invasive species are often threatened in their native range

acib: 3.6 Millionen Euro für Innovation in der biopharmazeutischen Produktion